Opus Genetics, Inc. (IRD) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US67577R1023
Opus Genetics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 14.20 m USD |
| Operating income | -38.60 m USD |
| EBIT | -49.46 m USD |
| Net income | -49.59 m USD |
| Diluted EPS – continuing operations | -0.80 USD |
Full history since 2009, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Opus Genetics, Inc.
Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs, including OPGx-RHO, a gene therapy that targets autosomal dominant retinitis pigmentosa caused by RHO mutations; OPGx-RDH12 that is designed to restore protein expression and halt functional deterioration in patients with retinal dystrophy caused by mutations in the retinal dehydrogenase gene; OPGx-MERTK, an AAV vector for the treatment of MERTK IRD; OPGx-NMNAT1, a gene augmentation therapy designed to halt functional deterioration in pediatric patients with retinal degenerative disease caused by mutations in the nicotinamide mononucleotide adenylyltransferase 1 gene; and OPGx-CNGB1, an AAV gene therapy for retinitis pigmentosa due to mutations in the CNGB1 gene. In addition, it develops Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as for the treatment of presbyopia and dim light or night vision disturbances and APX3330, a small-molecule inhibitor of Ref-1 for the treatment of diabetic retinopathy. Opus Genetics, Inc. was formerly known as Ocuphire Pharma, Inc. and changed its name to Opus Genetics, Inc. in November 2020. The company was founded in 2018 and is headquartered in Durham, North Carolina.
More stocks
- Samyang Holdings (000070.KS)
- Terra Innovatum Global N.V. (NKLR)
- UD Electronic (3689.TWO)
- Arcturus Therapeutics Holdings Inc. (ARCT)
- Maritima De In (MARINSA.SN)
- Trivago NV (TRVG)
- Kcc Glass Corp (344820.KS)
- Shiyan Taixiang Industry Co. Ltd. A (301192.SZ)
- Linedata Services S.A. (LIN.PA)
- Sam Yung Tradi (002810.KS)
- Zhubo Design (300564.SZ)
- Nexen Tire Prf 1 (002355.KS)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.